Open AccessA pilot study of angiogenin in heart failure with preserved ejection fraction: a novel potential biomarker for diagnosis and prognosis?
Author(s) -
Jiang Hong,
Zhang Lei,
Yu Ying,
Liu Ming,
Jin Xuejuan,
Zhang Peipei,
Yu Peng,
Zhang Shuning,
Zhu Hongmin,
Chen Ruizhen,
Zou Yunzeng,
Ge Junbo
Publication year - 2014
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.12344
Subject(s) - angiogenin , medicine , heart failure with preserved ejection fraction , cardiology , biomarker , ejection fraction , diastole , heart failure , natriuretic peptide , angiogenesis , blood pressure , biochemistry , chemistry
Abstract Characteristics of heart failure with preserved ejection fraction ( HFPEF ) have not yet been fully understood. The objectives of this pilot study are to detect protein expression profile in the sera of HFPEF patients, and to identify potential biomarkers for the disease. Five hundred and seven proteins were detected in the sera of healthy volunteers and patients with either HFPEF or hypertension using antibody microarrays (three in each group). The results showed that the serum concentrations of 17 proteins ( e.g . angiogenin, activin A and artemin) differed considerably between HFPEF and non‐ HFPEF patients (hypertensive patients and healthy controls), while a protein expression pattern distinct from that in non‐ HFPEF patients was associated with HFPEF patients. The up‐regulation of angiogenin in both HFPEF patients with LVEF ≥50% ( P = 0.004) and a subset of HFPEF patients with LVEF = 41–49% ( P < 0.001) was further validated in 16 HFPEF patients and 16 healthy controls. Meanwhile, angiogenin distinguished HFPEF patients from controls with a mean area under the receiver operating characteristic curve of 0.88 ( P < 0.001) and a diagnostic cut‐off point of 426 ng/ml. Moreover, the angiogenin levels in HFPEF patients were positively correlated with Lg(N‐terminal pro‐B‐type natriuretic peptide, NT ‐pro BNP ) ( P < 0.001). In addition, high angiogenin level (≥426 ng/ml) was a predictor of all‐cause death within a short‐term follow‐up duration, but not in the longer term of 36 months. This pilot study indicates that the aforementioned 17 potential biomarkers, such as angiogenin, may hold great promise for both diagnosis and prognosis assessment of HFPEF .